Oral contraceptives tied to lower risk of dysglycemia in women with PCOS: Study

UK: The use of combined oral contraceptive pills (COCP) in women with polycystic ovary syndrome (PCOS) reduces the risk of dysglycemia regardless of their body mass index, a recent study has suggested. The findings, published in the journal Diabetes Care, support "the recommendation that women with PCOS should be screened for type 2 diabetes irrespective of bodyweight category. 

Irregular menstrual cycles are related to increased cardiovascular mortality. PCOS is a hormonal disorder characterized by irregular menses and androgen excess. Androgens are known to increase metabolic risk in PCOS women. COCPs are used in PCOS both to reduce the biologically active androgen fraction and for cycle regulation. 

Against the above background, Balachandran Kumarendran, Institute of Applied Health Research, University of Birmingham, Edgbaston, Birmingham, U.K, and colleagues aimed to examine COCP use and risk of dysglycemia (prediabetes and type 2 diabetes) in women with PCOS.

For this purpose, the researchers carried out a retrospective population-based cohort study using a large U.K. primary care database (The Health Improvement Network [THIN]; 3.7 million patients from 787 practices). They determined dysglycemia risk (64,051 women with PCOS and 123,545 matched control subjects), as well as a nested pharmacoepidemiological case-control study to investigate COCP use in relation to dysglycemia risk (2,407 women with PCOS with [case subjects] and without [control subjects] a diagnosis of dysglycemia during follow-up).